Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HPV 16 E6 peptides vaccine/candida albicans extract

A human papillomavirus (HPV) type 16 vaccine containing four E6 peptides in combination with the extract of Candida albicans, with potential immunomodulating activity. Upon administration of HPV-16 E6 peptides vaccine/Candida albicans extract, the four HPV-16 E6 peptides and the candida albicans may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against cells expressing the E6 oncoprotein, resulting in tumor cell lysis. The HPV 16 transforming protein E6 is expressed in precancerous and malignant cervical lesions. Candida albicans allergenic extract may be used as a recall antigen to stimulate the immune system against HPV.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:HPV 16 E6 peptides vaccine/Candin
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search